Entropy Neurodynamics Strengthens Corporate Governance with Meghna Piplani as Joint Company Secretary

Meghna Piplani’s Expertise and Governance Qualifications

Meghna Piplani brings extensive legal and governance expertise to Entropy Neurodynamics. She holds a Bachelor of Law and a Master’s Degree in Business Policy and Corporate Governance, complemented by a Certificate in Governance Practice from the Governance Institute of Australia, underscoring her dedication to exemplary corporate governance standards.

With more than 11 years’ experience across public and private sectors in Australia and abroad, Piplani is well-equipped to navigate the complex regulatory landscape faced by ASX-listed biotechnology companies. Her diverse background enhances Entropy’s corporate governance as it manages regulatory submissions and stakeholder relations during clinical development.

Bio101 Financial Advisory and Healthcare Sector Alignment

Currently at Bio101 Financial Advisory, Piplani specialises in outsourced CFO, taxation, and company secretarial solutions tailored to the healthcare industry. This sector-specific expertise aligns closely with Entropy Neurodynamics’ focus on clinical-stage biotechnology and novel pharmaceutical development.

Piplani’s experience with healthcare governance supports Entropy’s management of regulatory pathways, ethics approvals, and clinical trial compliance essential for advancing psychedelic-assisted therapies. Her background strengthens the company’s capacity to address the unique challenges of this emerging therapeutic field.

Advancing Psilocin-Based Therapeutics with TRP-8803

Entropy Neurodynamics is developing proprietary intravenous psilocin formulations combined with psychotherapy to treat conditions with unmet medical needs. Its lead program, TRP-8803, offers advantages over oral psilocybin by enabling faster onset and improved control of the psychedelic experience.

Building on Phase 2a trials of oral psilocybin for Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia, TRP-8803 aims to shorten treatment duration to commercially viable timeframes, addressing key barriers to adoption and commercialization of psychedelic therapies.

Robust Corporate Governance with Dual Company Secretaries

The appointment of Meghna Piplani alongside Hamish George as Joint Company Secretary strengthens Entropy’s governance structure. George remains the primary contact for ASX communications under Listing Rule 12.6, ensuring compliance with continuous disclosure obligations.

This dual secretary model distributes governance responsibilities, enhancing oversight amid the company’s expanding clinical and regulatory activities. Piplani’s healthcare sector governance expertise complements George’s role, supporting comprehensive management of compliance and administrative demands.

Navigating Regulatory Dynamics in Psychedelic Therapy Development

Operating within a rapidly evolving regulatory environment, Entropy’s focus on intravenous psilocin formulations aligns with emerging clinical and regulatory standards for psychedelic medicine. Piplani’s appointment underscores the company’s commitment to maintaining rigorous governance and compliance frameworks tailored to this specialised sector.

Targeting indications such as Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia, Entropy addresses significant unmet needs where psychedelic-assisted psychotherapy shows promise. Piplani’s healthcare governance background aids in managing clinical trial and regulatory approval processes critical to advancing these novel treatments.

Academic Credentials and Governance Institute Recognition

Piplani’s academic qualifications include a Bachelor of Law, a Master’s in Business Policy and Corporate Governance, and a Certificate in Governance Practice from the Governance Institute of Australia, the nation’s leading governance authority. These credentials affirm her expertise in Australian corporate governance standards and ASX compliance requirements.

Her combined academic and practical experience equips her to provide strategic governance guidance as Entropy progresses through clinical development and regulatory milestones.

Enhancing Investor Relations and Shareholder Engagement

Adding Piplani as Joint Company Secretary bolsters Entropy’s capacity to maintain transparent investor communications during clinical development. The company utilises the Automic Group investor portal for shareholder engagement, encouraging investors to register for timely updates and electronic communications.

Her governance and healthcare sector experience supports effective disclosure of clinical progress, regulatory updates, and corporate developments, ensuring investors remain well-informed throughout the TRP-8803 program advancement.

Risk Management in Psilocin Therapeutics

The company acknowledges inherent risks associated with psilocin and related compounds, including temporary increases in blood pressure and heart rate, and potential psychosis risks in predisposed individuals. These effects are mitigated by low dosing and supervised clinical administration by specialist psychiatrists.

Entropy’s intravenous administration combined with psychotherapy is designed to optimize safety and efficacy. Piplani’s governance expertise supports adherence to regulatory and ethical standards critical for safe clinical trial conduct and future therapeutic approval.

Outlook and Next Steps in Clinical Development

Forward-looking statements in the announcement are subject to risks and uncertainties detailed in Entropy’s Replacement Prospectus, available on the ASX website at www.asx.com.au. This document outlines risk factors related to clinical programs, regulatory pathways, and the competitive psychedelic medicine landscape.

With Meghna Piplani’s appointment, Entropy reinforces its governance infrastructure as it advances TRP-8803 through clinical trials and regulatory submissions. Investors can track progress and receive updates via the Automic Group investor portal, ensuring ongoing engagement with the company’s developments.